Aryl sulfonic acids as FSH antagonists

Details Aryl sulfonic acids as FSH antagonists Aryl sulfonic acids as FSH antagonists

2000-03-24

2001-03-13

Powers, Fiona T. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...

C534S872000, C534S638000

Reexamination Certificate

active

06200963

ABSTRACT:

This invention relates to novel aryl sulfonic acids which function as FSH antagonists. More particularly, the compounds of this invention antagonize the binding of hFSH to its receptor and block cellular functions of FSH, including the production of second messenger cAMP and estradiol in ovarian and granulosa cells and are useful as female and male contraceptive agents.
BACKGROUND OF THE INVENTION
Reproduction in women depends upon the dynamic interaction of several compartments of the female reproductive system. The hypothalamic-pituitary unit orchestrates a series of events affecting the ovaries and the uterine-endometrial compartment which leads to the production of the ovum, ovulation, and ultimately appropriate conditions for fertilization. Specifically, hypothalamic hormones enhance the release of the gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). In the ovary, gonadotropins enhance the development of follicles which, in turn, secrete steroids (estradiol, progesterone) and peptides (inhibin, activin). Estradiol and inhibin levels progressively increase during the follicular phase of the menstrual cycle until ovulation. Afterwards, the follicular unit forms the corpus luteum which produces progesterone. Ovarian hormones, in turn, regulate the secretion of gonadotropins by establishing a classical long-loop negative feedback mechanism. The elucidation of these control mechanisms has provided opportunities for the development of effective strategies to control fertility, including both the enhancement of fertility and contraception. For recent reviews of FSH action see “FSH Action and Intraovarian Regulation”, B. C. J. M. Fauser, editor, Parthenon Publishing Group, 1997 and Hsueh, A. J., Bicsak, T., Jia, X. -C., Dahl, K. D., Fauser, B. C. J. M., Galway, A. B., Czwkala, N., Pavlou, S., Pakoff, H., Keene, J., Boime, I, “Granulosa Cells as Hormone Targets: The role of Biologically Active Follicle-Stimulating Hormone in Reproduction”
Rec. Prog. Horm. Res.,
1989, 45, 209-277.
Current hormonal contraception methods are steroidal and take advantage of long-loop feedback inhibition of gonadotropin secretion, as well as effecting peripheral mechanisms such as sperm migration and fertilization. An alternative strategy for hormonal contraception would be the development of specific antagonists of the receptor for FSH. Such antagonists would disrupt the actions of FSH on follicular development, thus producing the desired contraceptive effect. The utility of this strategy is supported by mechanism of infertility of women with resistant ovary syndrome. The infertility experienced by these women is the result of non-functional FSH receptors (K. Aittomaki, J. L. D. Lucena, P. Pakarinen, P. Sistonen, J. Tapanainnen, J. Gromoll, R. Kaskikari, E. -M. Sankila, H. Lehvaslaiho, A. R. Engel, E. Nieschlag, I. Huhtaniemi, A. de la Chapelle “Mutation in the Follicle-Stimulating Hormone Receptor Gene Causes Hereditary Hypergonadotropic Ovarian Failure”
Cell,
1995, 82, 959-968). This approach to contraception also appears applicable to men, since idiopathic male infertility seems related to a reduction in FSH binding sites. Moreover, men with selective FSH deficiency are oligo-or azoospermic with normal testosterone levels and present normal virilization. Therefore, orally active FSH antagonists may provide a versatile method of contraception.
Suramin Sodium, is an anticancer agent with a wide variety of activities. Recently suramin was shown to inhibit FSH binding to its receptor (Daugherty, R. L.; Cockett, A. T. K.; Schoen, S. R. and Sluss, P. M. “Suramin inhibits gonadotropon action in rat testis: implications for treatment of advanced prostate cancer”
J. Urol.
1992, 147, 727-732). This activity causes, at least in part, the decrease in testosterone production seen in rats and humans that were administered suramin (Danesi, R.; La Rocca, R. V.; Cooper, M. R.; Ricciardi, M. P.; Pellegrini, A.; Soldani, P.; Kragel, P. J.; Paparelli, A.; Del Tacca, M.; Myers, C. E, “Clinical and experimental evidence of inhibition of testosterone production by suramin.”
J. Clin. Endocrinol. Metab.
1996, 81, 2238-2246). Suramin is the only non-peptidic small molecule that has been reported to be an FSH receptor binding antagonist.
Prior art compounds include those of J. Dannheim, U. Reiher and W. H. Russ (EP 630946) disclosed compounds (A) and (B) as reactive dyes.
C. Schumacher and W. H. Russ (EP 675172) disclosed compound (C) as a water soluble reactive dye.
K. Kunder and K. J. Herd (E( 652262) disclosed compound (D) as a reactive dye.
H. W. Russ, H. Tappe and C. Schumacher (EP 629667) disclosed compound (E) as a reactive dye.
U. Reither, J. Dannheim and W. H. Russ (EP 624630) disclosed compound (F) as a reactive dye.
J. Dannheim and W. H. Russ (EP 513657) disclosed compounds (G) and (H) as reactive dyes.
J. Szadowski and Z. Niewiadomski [
Barwniki, Srodki Pomocnicze
1996, 40, 55-62] disclosed compounds (I) and (J) as dyes.
K. J. Herd, F. M. Stoehr and H. Hermann (EP 272532) disclosed compound (K) as a reactive dye.
H. Ischer and H. Siegrist (CH 463656) disclosed compound (L) as a reactive dye.
P. Grandjean (FR 1517223) discolosed compound (M) as a reactive dye.
Compound (N) (CAS registry no 67990-25-4) was disclosed.
L. Ruggli (
Helv. Chim. Acta
1939, 22, 1170-1177 disclosed the compounds of formula (O) and (P).
These prior art compounds do not possess the substitutions on the triazene or benzoyl rings seen in the present compounds of formula (I).
DESCRIPTION OF THE INVENTION
The compounds of this invention antagonize the binding of hFSH to its receptor and block cellular functions of FSH, including the production of second messenger cAMP and estradiol in ovarian and granulosa cells. The compounds of this invention are useful as female and male contraceptive agents.
The compounds useful in this invention have the general formula (I)
wherein
R
2
is CH
2
CH
2
CONH, or CH
2
CH
2
OH;
R
3
and R
4
are independent substituents from the group including H, —N(CH
3
)
2
, or —OCH
3
;
or pharmaceutically acceptable salts thereof.
Among the preferred compounds of this invention include the compounds of formula (Ia), below:
wherein R
3
and R
4
are independent substituents, as defined above, and:
when R
3
is from the group including H or 4-N(CH
3
)
2
; R
4
is H;
and when R
3
is 4-OCH
3
or 5-OCH
3
; R
4
is —OCH
3
;
or pharmaceutically acceptable salts thereof.
Other preferred compounds of this invention include the compounds of formula (Ib), below
wherein R
2
is —CH
2
CH
2
CONH
2
or —CH
2
CH
2
OH;
or pharmaceutically acceptable salts thereof.
Among the most preferred compounds in this invention are:
7-{4-[bis-(2-carbamoyl-ethyl)-amino}-6-chloro-[1,3,5]-triazin-2-ylamino}-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene-2-sulfonic acid (Example 3, 9);
7-{4-[bis-(2-hydroxy-ethyl)-amino}-6-chloro-[1,3,5]-triazin-2-ylamino}-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene-2-sulfonic acid (Example 11);
7-(3,4-dimethoxy-benzoylamino)-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene-2-sulfonic acid (Example 19);
7-benzoylamino-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene-2-sulfonic acid (Example 16);
7-(3,5-dimethoxy-benzoylamino)-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene-2-sulfonic acid (Example 14);
7-(4-dimethylamino-benzoylamino)-4-hydroxy-3-(4-methoxy-phenylazo)-naphthalene-2-sulfonic acid (Example 12);
or the pharmaceutically acceptable salts thereof.
This invention also comprises a method of inducing contraception in a male or female mammal, the method comprising administering to the mammal in need thereof a pharmaceutically effective amount of a compound of this invention, or a pharmaceutically acceptable salt thereof. The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers and/or excipients. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubiliz

Affiliated with

Also associated with

Rating

Aryl sulfonic acids as FSH antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl sulfonic acids as FSH antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl sulfonic acids as FSH antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2505454